Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III,Multicenter,Randomized,Open-label,Parallel-controlled Study Comparing the Efficacy and Safety of HRS9531 With Semaglutide in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Metformin Monotherapy or in Combination With SGLT2 Inhibitors

Next Previous
Trial Profile

A Phase III,Multicenter,Randomized,Open-label,Parallel-controlled Study Comparing the Efficacy and Safety of HRS9531 With Semaglutide in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Metformin Monotherapy or in Combination With SGLT2 Inhibitors

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Aug 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ribupatide (Primary) ; Semaglutide
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Fujian Shengdi Pharmaceutical

Most Recent Events

  • 04 Aug 2026 According to a Jiangsu Hengrui pharma media release, company intends to share data from the Phase III clinical trial of ribupatide injection at upcoming scientific conferences.
  • 04 Aug 2026 According to a Jiangsu Hengrui pharma media release, primary endpoint (Change in HbA1c) has been met.
  • 04 Aug 2026 According to a Jiangsu Hengrui pharma media release, based on positive results from this trial company plans to submit an NDA in China for ribupatide injection for glycemic control in adults with type 2 diabetes.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top